NEW YORK, NY / ACCESSWIRE / April 23, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a FY14 update on Youngevity International, Inc. (OTCQX: YGYI), a fast-growing, innovative, multi-dimensional company that is a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels.

The update note is available here: YGYI FY14 Update. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.

Ajay Tandon, CEO of SeeThruEquity commented, “Given the strong growth evidenced ahead of our model in 2014, and our expectations for continued growth in 2015E, we are increasing our price target to $0.61 for Youngevity. Our 2015E estimates call for revenue of $177.8mn and EBITDA of $8.6, with EPS of $0.01. If achieved the target would potentially represent 142.9% potential upside from the recent market price of $0.25.”

Additional highlights of the update note are as follows:

Robust revenue growth to end in 2014

Youngevity demonstrated robust revenue growth in 2014 with topline results that grew 56.5% from 2013 and exceeded our estimates. The company turned in revenue of $134mn, with impressive growth across the board. The Direct Selling segment grew 51% YoY to reach $116.4mn, while the Commercial Coffee segment more than doubled from 2013 levels, at $17.7mn.

Profitability continues with EPS of $0.01

We were pleased to see Youngevity report net earnings ahead of our model, with GAAP EPS of $0.01, flat versus 2013 and better than our estimate of $0.00. Results benefitted from a tax benefit, but overall the management team appeared to do a good job balancing investments in growth with striving to achieve financial returns. Youngevity generated $1.9mn in cash from operating activities during 2014, and ended the year with cash on hand of $3.0mn.

International expansion to drive growth in 2015

Youngevity has demonstrated robust growth with a nice mixture of organic efforts as well as acquisitions. We look for the company to continue its growth trajectory in 2015 by making strategic acquisitions and expanding its geographic presence. 94% of revenues originated in the United States during 2014, though with products now sold in 70 countries and territories, we expect international sales to be a greater part of the whole in the future. At the end of 2014 Youngevity had operations in the United States and New Zealand, and had subsidiaries in Australia, New Zealand, Russia, Mexico, Israel, Nicaragua and Colombia. We expect continued international expansion throughout 2015. Indeed, so far the company has announced new international expansions in Kazakhstan and Singapore, and appointed a new Country Manager for Canada, which is its largest foreign market measured by revenue at this time.

Please review important disclosures on our website at www.seethruequity.com.

About Youngevity International, Inc.

Youngevity International Inc., (YGYI) (www.YGYI.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a “network of networks.” The Company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. The Company was formed after the merger of Youngevity Essential Life Sciences (www.youngevity.com) and Javalution Coffee Company in the summer of 2011. Formerly known as AL International, Inc., the Company changed its name to Youngevity International, Inc. in July 2013.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 428122

NEW YORK, NY / ACCESSWIRE / April 23, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update on Pressure BioSciences (OTCQB: PBIO).

The report is available here: PBIO Update Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s. The report will also available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

“Although revenues declined slightly in 2014 versus 2013, this figure is skewed by the effect of a sharp drop in grant revenue from $0.46mn in 2013 to $0.03mn in 2014. We find the drop in grant revenue not hugely significant, especially in light of the company’s recent announcement that it has won a $1mn NIH grant payable over 2015 and 2016. More important in our view, is the fact that the core business trends at PBIO showed improvement during the year. In fact, revenues from products and services increased by 29% from $1.05mn in 2013 to $1.35mn in 2014,” stated Ajay Tandon, CEO of SeeThruEquity.

Mr. Tandon continued, “In light of what appears to be building momentum in its core products and services, as well as the completion of several key product enhancements, we are increasing our price target to $2.18 for PBIO. If achieved, the target represents potential upside of 560.6% from the recent price of $0.33. We now project 2015E revenue of $2.5mn, representing an increase of 81.9% YoY.”

Additional highlights of the update note are as follows:

Solid momentum developing in core products and services

PBIO displayed solid momentum in its core products and service offerings during 2014, with revenues in this area increasing by 29% to $1.35mn, versus $1.05mn in 2013. Consumables sales also increased YoY to reach $0.17mn. Total revenue of $1.4mn declined by 8.6% from 2013, largely due to the decline in grant monies, which, while important to the health of the company, mask underlying positive trends in the core products and services business. We see the momentum in product and services continuing for PBIO, as the company has begun shipping its next generation high throughput product line, the Barozyme HT48. We see the product, which can process up to 48 samples at a time, as having significant potential because it integrates the PCT-based sample preparation platform into modern laboratory operations that leverage robotic automation for high throughput handling and sample processing.

PBIO receives $1mn NIH SBIR Phase II grant

On February 19, 2015 PBIO announced that it had received a $1.02mn SBIR Phase II grant from the National Human Genome Research Institute of the NIH. The grant provides non-dilutive financing for PBIO, payable over two years, to support the development of a high pressure-based system for the preparation of samples for DNA analysis by next generation sequencing (NGS) methods. We view this as an extremely positive development for PBIO as NGS represents a large market opportunity for PBIO and was already a part of the company’s growth plans.

Positive outlook for robust growth in 2015

PBIO management articulated a goal to reach $2mn in revenue during 2015. The company believes the traction from its recent product introductions will enable PCT products and services to grow at a faster rate than in 2014 – when they grew 29% – and also sees growth in consumables. With the announcement of the NIH grant, the goal of surpassing $2mn in revenue seems achievable, in our view. We have forecast revenue of $2.5mn for PBIO in 2015E, which implies annual top line growth of 81.9%.

Increasing price target to $2.18

In light of what appears to be strong momentum in its core products and services, as well as the completion of several key product enhancements, we are increasing our price target to $2.18 for PBIO. If achieved, the target represents potential upside of 560.6% from the recent price of $0.33.

Please review important disclosures on our website at www.seethruequity.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. PBIO’s primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use its products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 428127

NEW YORK, NY / ACCESSWIRE / April 23, 2015 / Cancer immunotherapy is scorching hot. At no time in medical history has a new cancer treatment been so widely researched and highly paid for. Over the last 50 years, the only medicine for cancer has been radiation and chemotherapy, and a few monoclonal antibodies with side effects not much better, barbaric compared to this new wave of ways to combat the disease.

Leading this charge is CEL-SCI Corporation (CVM:NYSE MKT), far above competitors, in Phase III clinical trials with Multikine, a potent cocktail of immune system activators for head and neck cancer (and other infectious diseases). After a misstep with an incompetent contract research organization (CRO) to run studies, the company regrouped and hired two global oncology experts – Aptiv Solutions and Ergomed, the latter which, also serving multi-billion dollar Sanofi (SNY:NYSE), will contribute up to $10 million to the development of Multikine for its cancer indication in exchange for a very small royalty payment when the drug is approved and on the market. I credit the savvy of Cel-Sci’s CEO, Geert Kersten, long-time advocate of the technology, for inking this terrific deal.

Ergomed, true to a unique model for filling clinical trial beds, helped Cel-Sci report its third consecutive month of record patient enrollment so far this year in the head and neck cancer study, bringing the total to over 400. Cel-Sci’s goal is 880 subjects and looks on track to complete this number by year end. The latest clinical center to join the trial is Aintree University Hospital in the UK, led by a specialist in head and neck cancer from a prestigious facility in Liverpool, bringing on board another country very close to the company’s goal of 100 clinical sites in 25 countries.

Investors should be impressed. The Multikine Phase III study is aimed at patients with advanced head and neck cancer, but not yet treated, a more difficult pool to choose from. Head and neck cancer, a horribly disfiguring disease, inflicts 600,000 new people worldwide every year and accounts for almost 10% of new cancer cases in the US. Globally, the market size is $3.2 billion. There is a clear need for alternatives to scarring surgery, not to mention the devastating effects of standard chemotherapy.

Multikine’s clinical trial endpoint is a 10% improvement in overall survival with subjects treated with the drug versus standard of care, not a hard hurdle to meet. When accomplished, approval applications for Multikine can be made in all the countries where clinical trials are held, giving Cel-Sci a wide global reach for upcoming sales.

With a market cap of just $85 million, CEL-SCI is blatantly undervalued as a Phase III cancer immunotherapy company. Look at recent transactions for cancer immunotherapy: Cellectis SA (CLLS:NASDAQ), an IPO backed by high-powered underwriters, recently raised nearly $230 million and stands with a market cap of $1.1 billion, spurred to new heights with an up-front payment from Pfizer, Inc. (PFE:NYSE) of $80 million.

Juno Therapeutics (JUNO:NASDAQ), another newcomer in cancer immunotherapy barely out of Phase I, took investors for $265 million last year. Bellicum Pharmaceuticals, Inc. (BLCM:NASDAQ), in early trials went public at $140 million with a current value of $681 million. Kite Pharma, Inc. (KITE:NASDAQ), another recent public offering, trades at a $2.8 billion market capitalization, based solely on an early-stage cancer immunotherapy hopeful, in head and neck cancer.

A close peer to Cel-Sci, Inovio Pharmaceuticals (INO:NASDAQ) doing studies in head and neck cancer caused by human papilloma virus (HPV) and only in Phase I/IIa boasts a valuation of $609 million. ImmunoGen, Inc. (IMGN:NASDAQ), early in Phase I for head and neck with a cancer immunotherapy, has investors paying $10 per share with a market cap of $871 million. Transgene SA (TNG.PA:Paris) is enrolling for Phase II in HPV-induced cancer, developing a vaccine for head and neck – market cap is $230 million.

ZIOPHARM Oncology, Inc. (ZIOP:NASDAQ) is in Phase II with immunotherapy for solid cancers with a value of $1.2 billion. Puma Biotechnology (PBYI:NYSE), in various stages of clinical trials with one drug, PB272 for breast cancer, is valued by investors at $7.4 billion. Celldex Therapeutics (CLDX:NASDAQ), in mid-stage trials for brain cancer using immunotherapy would, if successful, sell to a market much smaller than Cel-Sci’s yet is valued at $2.4 billion.

Big Pharma is throwing big dollars around for cancer immunotherapy. Bristol-Myers Squibb (BMY:NYSE) pays $800 million for privately-held Flexus Biosciences with milestones leading up to $1.25 billion, and struck a deal with Rigel Pharmaceuticals (RIGL:NASDAQ) for exclusive rights to develop drugs from Rigel’s technology to inhibit tumor growth, costing Bristol around $340 million. AbbVie Inc. (ABBV:NYSE), spun off from Abbott Laboratories (ABT:NYSE) agreed to buy Pharmacyclics Inc. (PCYC:NASDAQ) for a stake in their new cancer immunotherapy drug Imbruvica, at an astounding $21 billion.

Multinational giant Johnson & Johnson (JNJ:NYSE), the Band-Aid and Tylenol company, and Novartis AG (NVS:NYSE), known best for its diabetes products, both backed cancer immunotherapy purveyor Aduro Biotech (ADRO:NASDAQ) for a recent IPO that sent the stock soaring at its opening, priced at $17 and opening at $32.

Cel-Sci has been unfairly ignored in this race for cancer immunotherapy drugs. This stock has seen momentum and I expect more. In early March, shares jumped when the company announced record patient enrollment in February, with volume 200% above average trading. Cel-Sci’s news keeps getting better. Besides head and neck cancer, Multikine drew attention from the US Naval Medical Center in San Diego resulting in a deal under the government’s coveted CRADA (Cooperative Research and Development Agreement) to study the drug for sexually transmitted disease – apparently a big problem in the armed forces. The University of Maryland also investigates these conditions for Cel-Sci in a Phase I trial. All said, this company has a broad reach for its potential to work with the body’s immune system to attack tumors.

Success in any of Cel-Sci’s clinical trials for Multikine, a pivotal-stage cancer immunotherapy drug, could reward the stock with a huge jump in hundreds of millions of dollars in valuation.

RAY DIRKS Research suggests that Readers/Investors place no more than 1% of the funds they devote to common stocks in any one issue. It’s best to diversify.

About Ray Dirks

Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high -net worth investors both in the U.S. and internationally.

In 1973 Ray uncovered the biggest Ponzi scheme of the 20th century, the Equity Funding fraud. Over the years Ray has expanded his stock market research to include Healthcare Stocks and Special Situations. Ray has written two books,”The Great Wall Street Scandal” and “Heads You Win, Tails You Win”, published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals, and he manages money for some individual investors.

Media contact:

Jackie Rodriguez, Marketing Manager
JVPR NY
646-430-5783

SOURCE: Ray Dirks Research

ReleaseID: 428125

PHOENIX, AZ / ACCESSWIRE / April 23, 2015 / Lithium Exploration Group Inc. (PINKSHEETS: LEXG), announced today that the replacement shaft for the SonCav Ultrasonic Generator is ready to ship from the manufacturer’s facility in Austria. (The unit was damaged in transit in February of this year.) While the shipment will still need to go through normal customs procedures, it is expected to arrive in Spring, TX, by the end of next week.

“We are obviously excited to have the shaft kit ready to ship. The team in Spring is ready to begin reassembly, and we will get the unit ready to ship to Alberta as soon as possible,” commented CEO Alex Walsh. “Now that we have some timing in place, we can resume our planning process and report back next week on timing and next steps.”

About Lithium Exploration Group

Lithium Exploration Group is a US-based exploration and development company focused on the acquisition and development potential of lithium brines and other precious metals that demonstrate high probability for near-term production. Currently the company is focused on its Western Canada lithium assets, testing its Ultrasonic Generator Technology and the acquisition of oil and gas related assets in Western Canada. Lithium Exploration Group is a fully reporting company traded on the OTC Markets under the symbol LEXG. Website: www.lithiumexplorationgroup.com.

Safe Harbor Statement

This news release contains “forward-looking statements”. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future testing of the ultrasonic technology.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of lithium prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

CONTACT:

Shanon Chilson
480-641-4790
info@lithiumexplorationgroup.com

SOURCE: Lithium Exploration Group Inc.

ReleaseID: 428146

MOUNT PLEASANT, UT / ACCESSWIRE / April 23, 2015 / Green PolkaDot Box (PINKSHEETS:GPDB) America’s premier online buying collective for organic and non-GMO natural foods at wholesale pricing. Announced today, a decision to Limit the number of Health Merchants in 2015 to 2,000 this limitation will insure GPDB has the service infrastructure, distribution facilities and inventory supplies in place before further increasing the Health Merchant Program. Based on early response and participation from Moms Across America and given our marketing plans for a national Health Merchant “Commitment” Tour in May, the company expects to hit our goal of 2,000 Health Merchants by the end of July.

CEO Rod Smith issued the following announcement, “The Health Merchant agreement with Moms Across America announced earlier this week is a foreshadowing of things to come. I believe that our efforts will attract many individuals and organizations; will unite their missions with GPDB to join the growing CLEAN food revolution. The Health Merchant program offers a one-of-a-kind opportunity for “influencers” to provide their followers, constituents, customers and patients with affordable access to CLEAN foods and create a recurring revenue stream to support their cause.”

“As I have thought about this eventuality and its impact on our company, I came to the conclusion that the public might be interested to understand what it means to have 2,000 Health Merchants in the GPDB buying collective,” stated Rod Smith, C.E.O. “2,000 Health Merchants, each having 100 customers by March 1, 2016, each spending an average of $150 monthly, means that GPDB revenues could increase sharply to more than $30 million, monthly. Again, that’s a projected total of at least 200,000 customers shopping and spending $30 million at the Health Merchants’ stores, collectively, on a monthly basis.”

The Impact of 2000 Health Merchants on GPDB’s Plan for Vertical Integration

It is easy to understand they the pricing for the clean foods we offer will fall sharply as Health Merchants increase customers and orders. The projection of $30 million in monthly sales would mean that inbound food shipments would be arriving at our distribution centers by the truckload instead of the case, driving unit costs down by as much as 20%. The sales volume would enable distribution centers in Utah, Tennessee and Texas, cutting down shipping distance and costs by as much as 50% while increasing speed of delivery to no more than two days. The net affect of this increase in sales could be a 20-25% price reduction across most food items we carry, not including discounts from special sales and promotions.

But the potential impact is even greater as I’ve written about our plans to become vertically integrated by growing clean foods, starting with Living Produce(R). I come back to this point because when we achieve $30 million in monthly revenues through the efforts of 2,000 Health Merchants, each with 100 active, shopping customers, not only will our prices drop because of greater efficiency, larger orders and reductions in cost, we will also have a much higher market valuation; it will be easier to raise capital for investment to expand Living Produce Growing Centers and distribution, and acquire other agricultural properties.

Formula for Success

2000 Health Merchants and their customers is just the beginning we have found the formula for success; it is the establishment of our Health Merchant program. The public should be able to see how close we are moving closer to achieving our goal to becoming the largest buying collective in America for organic and non-GMO foods at affordable prices with free home delivery.

About Green PolkaDot Box

Green PolkaDot Box is America’s premier online buying collective for organic and non-GMO natural foods at wholesale pricing. The Company leverages proprietary technology and products with its dynamic, interactive website and customer relationship management software to provide a unique shopping experience. The Company also empowers other businesses and organizations to establish an online Health Merchant store-a non-stocking distributorship-for their own benefit. For more information on Green PolkaDot Box, visit: www.greenpolkadotbox.com.

Safe Harbor Statement

This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as GPDB or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” “Plans” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

Investors Relations Contact

Rod Smith
CEO/Green PolkaDot Box Incorporated
(801) 787-8835
rsmith@greenpolkadotbox.com

SOURCE: Green PolkaDot Box Incorporated

ReleaseID: 428133

VANCOUVER, BC/ ACCESSWIRE / April 23 2015 / Mission Ready Services Inc. (TSX-V: MRS) – Mission Ready Services Inc. (“MRS” or the “Company”) is pleased to provide an update on the advancement of its Next Generation Body Armor System currently in the final stages of prototyping and user evaluations.

MRS has been a close and trusted partner of the US Army in the development of a new upper extremity system and both have been heavily involved in the concept and design of the item. MRS built 36 units for the first user evaluations in May 2014 which due to overwhelming approval ratings resulted in the Army elevating the program to department level II testing. Taking user feedback and the Army’s guidance the Company built an additional 100 units for second and third user evaluations conducted in early 2015.

Users have commented on the athleticism and greater mobility of the system when compared to current standard issue protective garments such as the Improved Outer Tactical Vest deltoids, neck, yoke & collar and upper back. The new system integrates all of these modular items into a single upper extremity system and is lighter than the combined total of the current modular items while providing greater protection. User comments so far have been very positive and MRS continues the goal to increase/improve a soldiers performance and the Company believes that this system does that better than anything available today. The Company is systematically looking at future improvements of the system to meet certain mission or user unique requirements.

In a News Release dated August 12, 2014, Mission Ready announced the filing of a patent application with the US Patent Office as well as an international filing under the Patent Cooperation Treaty for its Integrated Body Armor Garment.

The Global Body Armour and Personal Protection Market 2012-2024 – Market Size and Drivers: Market Profile by Report Buyer indicates that the Body Armor and Personal Protection market for military and law enforcement is currently estimated to be over US $3 billion and is forecast to increase to over $5 billion within the next 10 years. The market is driven by soldier modernization programs and due to the globally increasing demand by law enforcement agencies.

About Mission Ready Services Inc.

MRSI was created to meet a critical need of one of the world’s largest customers, the US Government and in particular the Departments of Defence, Homeland Security and Justice and various other agencies such as law enforcement, first responders and the many others worldwide that help to safeguard our health and security.

MRSI’s mission is to save lives and enhance the performance of military personnel, first responders, and those who protect us by working to ensure they are equipped with the best possible personal protective equipment.

For further information, visit the Company’s website at MissionReady.ca or contact:

Terry Nixon – Director, Corporate Communications

Telephone: 1.877.479.7778

Investor Relations

1-866-684-6730

mrs@kincommunications.com

www.kincommunications.com

Mission Ready Services Inc.

(signed “Rod Reum”)

Rod Reum,

President & CEO

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “forecast”, “project”, “budget”, “schedule”, “may”, “will”, “could”, “might”, “should” or variations of such words or similar words or expressions. Forward-looking information is based on reasonable assumptions that have been made by Mission Ready Services Inc. as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Mission Ready Services Inc. to be materially different from those expressed or implied by such forward-looking information.

Forward-looking statements are based on assumptions management believes to be reasonable. Although Mission Ready Services Inc. has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Mission Ready Services Inc. does not undertake to update any forward-looking information that is included herein, except in accordance with applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Mission Ready Services Inc.

ReleaseID: 428149